Executives, leaders, and social media marketing heads from leading colleges and universities will gather at the Social Media Strategies Summit for Higher Education 2025. Tickets include access to the Higher Ed Summit on October 20–21 and access to the Corporate Brand Summit on October 23–24. The workshops are optional and can be accessed through separate registration. Attractive early bird offers are available.

Experts will conduct sessions on October 20-21, 2025, where they explore and share insights on the best social media marketing practices for colleges and universities. Eminent professionals from the higher education social media marketing realm all across the country will attend the conference to share important knowledge on the newest and best social media marketing strategies.

The event is a mammoth learning platform for executives and professionals in recruitment, admissions, social media marketing, and student experiences, where they can connect with peers and industry leaders to share and learn the best practices.

The two-day conference will feature speaker sessions, panel discussions, a live chat stream, and a Q&A session, where attendees can have their queries addressed by experts. Three of the speakers will also host the ‘Ask Me Anything’ session, where they will explore relevant topics to offer unique insights and perspectives.

Experts will also navigate important topics, such as the role of AI in social media, translating data into strategic insights, building a thriving community on social media, amplifying student voices while maintaining a positive reputation, and more.

For the last 11 years, the SMSsummit has successfully offered the latest research, tools, and strategies that add value to the existing skill set of social media marketing for universities and colleges.

To learn more, please visit https://ibn.fm/aKv4A.

The 5th Investigator-Initiated Trials Summit will take place in Philadelphia on November 13–14, 2025. 

As the premier gathering for life sciences professionals driving IIT programs, this event unites clinical leaders, researchers, and industry experts to dissect common challenges happening in the IIT space. 

Investigator-initiated research continues to serve as a cornerstone of clinical innovation, creating opportunities to explore new indications, expand therapeutic options, and improve patient outcomes.

Hosted by Dynamic Global Events, the 5th IIT Summit features a distinguished speaking faculty offering proven strategies to streamline study activation, meet your study milestones, go over bottlenecks in clinical contracting, and much more!

Whether you join us in person in Philadelphia or virtually via our interactive platform, the IIT Summit provides the insights and connections you need.

Topics Covered Will Include:

• Meet Your Milestones for Smoother Trial Execution
• Leverage Dashboards to Drive Accelerated Trial Activation
• Analyze Contracting Challenges and Negotiation Techniques
• Fill Gaps in Clinical Practice and Advance Unanswered Medical Questions
• Build a connected ecosystem to accelerate scientific breakthroughs and discoveries in Academic Medical Centers
• Examine The Challenges that Accompany Collaborative Research

Register today to secure your spot for this year’s Investigator Initiated Trials Conference! 

To learn more, please visit https://ibn.fm/8QVuN.

• GlobalTech Corp. Is a tech holding company that specializes in AI, big data, digital infrastructure, the cornerstone of the company’s growth
• It has a portfolio of AI-powered products and companies in numerous industries, such as education, sports, E-commerce, hiring, and others
• The company recently announced closing of a $1.4 million convertible note private placement, with the proceeds being used to support strategic priorities

GlobalTech (OTC: GLTK) is a technology holding company that specializes in industries like AI, big data, and digital infrastructure. The company continues to evaluate technology-centric acquisitions while also expanding through strategic regional alliances.

GLTK has a strong portfolio of products and acquisitions in a variety of industries like digital lending, compliance, retail, sports, recruitment, and eLearning/training. This includes solutions like Cadnz, ThrivoAI, Baseball Blitz and others.

Cadnz is a lending-lifecycle management platform aimed primarily at US banks and credit unions. The platform’s tools are focused on streamlining workflows, improving risk monitoring, and making decision-making faster and more accurate. Cadnz positions itself as a “smart, integrated solution” to reduce friction in lending and to help financial institutions handle origination, risk, and compliance more efficiently.

ThrivoAI is a business amplification platform that unifies business intelligence from every touch point into one ecosystem. The platform aims to help you boost conversions, improve consistency, and increase performance. It connects all stages of your value chain and improves decision-making and customer understanding by organizing data and turning it into actionable insights.

Baseball Blitz is a digital hub for all things baseball, and offers everything from league management to player development, fan engagement, and scouting. It lets you schedule games, track stats, manage teams, provide real-time updates, show off player profiles and highlights, and more.

In addition to their vast enterprise solutions, GlobalTech Corp. has also recently announced it has closed a convertible note private placement funding of $1.4 million. The notes are automatically convertible to common stock (at a 15% discount) upon a future IPO for GlobalTech Corp.

The proceeds from this investment are being used to fund and support various strategic priorities, including developing AI-powered solutions, expanding into high-growth international markets, and potentially making more acquisitions.

About GlobalTech Corp. (GLTK)

GlobalTech Corp. is a technology holding company with a focus on AI, big data and digital infrastructure. The company’s enterprise spans many AI solutions across industries and helps unlock the full potential of these organizations and platforms by offering access to capital markets and cutting-edge technologies.

For more information, visit www.GlobalTechCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to GLTK are available in the company’s newsroom at ibn.fm/GLTK

• Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003
• Sapu003 uses Sapu Nano’s Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form
• Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited

Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.

Sapu003 is an injectible from of Affinitor(R) (Everolimus), which is an FDA-approved drug for treating different types of advanced cancer including breast cancer, kidney cancer, and affiliated rare tumors.

When taken orally in pill form, only about 10% of the drug is absorbed by the body, limiting how effective it can be. With that in mind, using Sapu Nano’s novel Deciparticle(TM) technology, Sapu003 that’s injected intravenously opens 100% of the drug reach the bloodstream.

As a result, Sapu003 represents a new approach to administering an existing cancer drug. Delivering the drug intravenously lets researchers give it at full strength, which may make it more effective at reducing the size of tumors.

This first trial aims to see if this improved version of the drug gives breast cancer patients not only new hope, but also more long-term and enduring benefits.

Dr. Vuong Trieu, the CEO of Sapu Nano, stated, “We are extremely pleased to receive approval from HREC to proceed with human clinical trials,”. He also added that “Despite advances in treatment, a critical unmet need for next generation mTOR inhibitors remains. Current therapies often extend progression-free survival for less than one year and rarely deliver long-term disease control. This Phase 1 trial will allow us to determine the best dose for future studies, including a Phase 3 trial. (ibn.fm/dY3G0)”

Dr. Sud Agarwal, CEO of Ingenu, a contract research organization (“CRO”) in Australia, added that “the approval of Sapu003 to enter human trials is a landmark moment. By enabling full drug absorption through intravenous delivery, this program has the potential to achieve meaningful tumor shrinkage where oral formulations have been limited. We are proud to support Sapu Nano in advancing this therapy, potentially giving breast cancer patients better outcomes and improved quality of life.”

About Oncotelic Therapeutics, Inc. 

Oncotelic Therapeutics is a biopharmaceutical company that develops therapeutics for cancer and other underserved diseases. The company has a portfolio of clinical-stage candidates and is focused on transforming outcomes for patients suffering from rare and/or difficult-to-treat conditions.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

• The electronic monitoring (“EM”) company won Germany’s national EM  contract, valued at up to $7 million over four years.
• SuperCom displaced a provider that had supplied the country’s EM technology for more than 20 years.
• Germany becomes the ninth nation to adopt SuperCom’s domestic violence solution.
• Contract covers multiple programs, including GPS tracking, domestic violence monitoring, home detention, and alcohol monitoring.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has been awarded a national electronic monitoring (“EM”) contract in Germany, marking a strategic expansion into Europe’s largest economy. The program budget is estimated at $7 million over four years, with actual revenues depending on usage levels, according to a company news release (https://ibn.fm/83moK).

The contract was secured through a competitive tender that included multiple global vendors. For more than two decades, Germany’s EM systems had been provided by the same supplier. SuperCom’s selection reflects a shift in how European governments are approaching offender monitoring and domestic violence prevention.

Germany is recognized as one of Europe’s pioneers in electronic monitoring, with over 25 years of experience in the field. The decision to move away from its longstanding vendor highlights both the maturity of the German market and the demand for more adaptable, technology-driven platforms.

“Securing this award after a highly competitive process is a powerful validation of our technology and execution capabilities globally. This is more than a contract win, it is a strategic milestone that demonstrates how our PureSecurity Suite meets the highest standards for modern public safety solutions,” Chief Executive Ordan Trabelsi said. “We are honored to support Germany’s evolving EM programs with our proprietary, field-proven technology.”

SuperCom will deploy its PureSecurity(TM) Suite, which integrates GPS tracking, RF technology, multi-factor biometrics, and secure communications. The system supports a variety of public safety applications, including domestic violence prevention, home detention, alcohol monitoring, and broader community supervision.

Germany becomes the ninth nation to adopt SuperCom’s domestic violence solution. The platform includes PureProtect(TM), a mobile app that alerts victims if restrictions are breached. The app utilizes advanced zoning, proximity, alerting, and management capabilities to both enforce a safe distance between victims and perpetrators and update the former on the latter’s whereabouts. Together with GPS-enabled PureOne(TM) tracking bracelets and PureMonitor(TM) software for law enforcement, these tools offer a comprehensive framework for safeguarding victims while ensuring offender compliance.

Electronic monitoring has been linked to reduced recidivism in several international studies. Research from Argentina found a 48% reduction in one-year reoffending rates, while studies in Australia and France reported decreases of 28% and 10% respectively. These outcomes suggest EM programs not only improve public safety but can also reduce the economic burden of traditional incarceration.

By offering modular, scalable technology, SuperCom positions itself as a provider capable of supporting both large national projects and smaller regional programs.

The German award builds on SuperCom’s momentum in Europe, where it has secured more than 15 national EM projects. In the United States, the company has added over 30 contracts in the past year alone. Trabelsi emphasized that initial contracts often expand into additional opportunities as governments gain confidence in the technology.

“While this new contract in Germany already spans four programs, we are also excited about the additional opportunities our technology can help unlock as needs evolve,” Trabelsi added. “We look forward to supporting Germany in this important project and further strengthening our role as a trusted partner to governments worldwide seeking innovative and effective public safety solutions.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development timelines, reduce risk, and improve candidate selection.
• This technology helps determine whether or not a candidate is able to cross the blood-brain barrier or not, which is a major holdup for many drug development companies.
• Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the collaboration and how it can help deliver life-changing therapies for patients.

Hoth Therapeutics (NASDAQ: HOTH), a biopharmaceutical company, recently announced that the company is using an AI-powered platform developed by Lantern Pharma (NASDAQ: LTRN), a clinical-stage biotech company and pharma, to streamline and improve the drug development process (https://ibn.fm/VIL67).

The platform, called PredictBBB.ai(TM), is a next-gen AI tool that was designed to help determine whether a drug candidate is able to cross the blood-brain barrier. This is a common bottleneck in drug development, and Lantern Pharma’s platform offers 94% accuracy in predicting whether or not different compounds are able to permeate the blood-brain barrier.

With the help of this cutting-edge platform, Hoth Therapeutics can use AI-powered insights to lessen uncertainty, reduce risk, boost precision, speed up timelines, and improve candidate selection.

The PredictBBB.ai tool is a part of a larger platform being developed by Lantern Pharma, called RADR®, which stands for Response Algorithm for Drug Positioning & Rescue. The platform is used to predict the responses patients may have to different drugs, and also to help in the process of developing target compounds to fight against cancer.

Leadership at both Lantern Pharma and Hoth Therapeutics are enthusiastic about the partnership, and what it means for cancer patients.

Lantern Pharma CEO Panna Sharma said “At Lantern Pharma, we’re very enthused by the early adoption of our PredictBBB.ai platform by innovators like Hoth Therapeutics. This online service, which is a part of our RADR platform, has the potential to be a game-changer in CNS drug development. This cutting-edge AI tool, with its 94% accuracy in predicting blood-brain barrier permeability, is empowering researchers to make faster, smarter decisions, accelerating the path to life-changing therapies for patients worldwide.”

Echoing this excitement, Hoth Therapeutics CEO Robb Knie added that “Our integration of Lantern’s PredictBBB.ai tool aligns with our mission to deliver life-changing therapies while driving efficiency, reducing costs, and unlocking new opportunities for patients and shareholders alike.”

About Lantern Pharma Inc. (NASDAQ: LTRN)

Lantern Pharma Inc. is an oncology-focused, clinical stage pharma that’s concentrating on artificial intelligence, genomics, and machine learning. Applying and expanding cutting-edge AI technology, the company has the mission of delivering precision oncology therapies with reduced costs and timelines.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

• SuperCom has secured a new electronic monitoring project with a sheriff’s department in Wisconsin, marking the company’s 12th new U.S. state entry since August 2024.
• The company has signed over 30 contracts and 11 reseller partnerships in the U.S. during the same period.
• The project introduces a domestic violence prevention program and may expand into GPS tracking, as the company deploys its PureSecurity(TM) platform, offering modular GPS, RFID, and mobile solutions tailored to public safety needs.
• Research indicates electronic monitoring programs can reduce recidivism rates.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has expanded into its 12th U.S. state through a new electronic monitoring (“EM”) project in Wisconsin. The company announced on September 17 that, in partnership with a Midwest service provider, it will deploy its PureSecurity(TM) EM technology for a sheriff’s department program (https://ibn.fm/QWdMu).

The Wisconsin agency is launching a domestic violence prevention initiative using SuperCom’s system, with plans to expand into GPS-based offender tracking. The selection followed a review of multiple technology providers, with SuperCom chosen for its precision, reliability, and mobile integration. The project is structured under a recurring revenue model, billed monthly based on active daily units.

“This latest win further validates a nationwide shift toward more modern, effective electronic monitoring systems,” said CEO Ordan Trabelsi. “Agencies continue to upgrade from legacy solutions and choose SuperCom with our field-proven technology, rapid deployment capabilities, and track record of delivering measurable improvements in public safety.”

The Wisconsin deployment adds to SuperCom’s record of rapid U.S. expansion. Since August 2024, the company has entered 12 new states, signed over 30 contracts, and formed 11 reseller agreements. These agreements come against a backdrop of rising demand for tools that support alternatives to incarceration. The company’s projects typically focus on offender monitoring, probation programs, and domestic violence prevention.

The recurring revenue model used for these contracts provides predictable income streams. Each new program increases the company’s installed base, which can be expanded through add-on services and complementary solutions.

SuperCom’s EM solutions are built on its PureSecurity platform, a modular system that integrates GPS, RFID, and cloud-based monitoring technologies. The platform is adaptable, allowing jurisdictions to scale programs according to specific needs.

Key offerings include:

• PureOne(TM): a GPS-enabled wearable tracking bracelet.
• PureShield(TM): used in domestic violence cases to enforce exclusion zones and restraining orders.
• PureProtect(TM): a mobile phone and app that alerts victims when restrictions are violated.
• PureMonitor(TM): real-time monitoring software designed for law enforcement agencies.

Additional devices, such as PureCom, PureTag, PureBeacon, and PureTrack, can be deployed to tailor solutions for house arrest, parole, or community-based supervision.

SuperCom’s focus on EM aligns with global evidence showing that monitoring reduces recidivism. Research from Argentina found EM cut the one-year re-offense rate by up to 48%. In Australia, a two-year study showed a 28% reduction, while data from France suggested a 10% decrease in re-offending over five years.

These findings support EM as a cost-effective alternative to incarceration that also aids rehabilitation. Programs like the one now launching in Wisconsin are seen as contributing to both public safety and economic stability.

SuperCom’s model blends technology sales with ongoing service revenue, a structure that has attracted repeat contracts in multiple jurisdictions. The company’s rapid U.S. expansion underscores its ability to win contracts in a competitive market. Each state entry builds brand recognition and strengthens its reseller network, making future adoption more likely. 

“Each win adds to our long-term recurring revenue base and reinforces our expanding footprint. With more than 15 national projects awarded globally and increasing demand for our domestic violence solutions, we’re proud to be the trusted partner governments turn to when seeking to modernize and scale public safety infrastructure,” Trabelsi said. “These achievements come on the heels of record net income and expanded gross margins in the first half of 2025, enabling us to scale and deliver exceptional value to our clients and stakeholders.”

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using its proprietary drug candidates and computational biology and machine learning platform, to target conditions with unmet medical needs
• A recent Type C meeting with the U.S. Food and Drug Administration provided the company with guidance in working through the regulatory pathway and designing the trial for its investigational therapy LP-184/STAR-001, which will seek a means of battling pediatric brain cancers
• Lantern Pharma is also using drug candidates in trials to combat glioblastoma (“GBM”), triple-negative breast cancer, non-small cell lung cancer in non-smokers, non-Hodgkin’s lymphoma, and other tumors
• Lantern’s meeting with the FDA will help it amend its investigational new drug (“IND”) submission for the potential pediatric central nervous system cancer therapy LP-184/STAR-001 and a planned trial launch in Q1 of 2026
• Two of the company’s current trials achieved a complete response in patients during the past quarter

Clinical-stage cancer technology company Lantern Pharma (NASDAQ: LTRN) is preparing for the launch of a trial targeting a rare pediatric disease, planned for Q1 2026, in the wake of the company’s optimistic meeting with the U.S. Food and Drug Administration (“FDA”) to receive critical guidance on the company’s trial design and the FDA’s regulatory pathway.

Lantern Pharma is developing its clinical trial with the hope of demonstrating the efficacy of its investigational therapy LP-184/STAR-001 in combatting central nervous system (“CNS”) cancers, including Atypical Teratoid Rhabdoid Tumor (“ATRT”). The LP-184/STAR-001 therapy is designed to work synergistically with diuretic (water pill) spironolactone (https://ibn.fm/JksRT) and other potential combination regimens in treating the childhood brain cancers classified as unmet medical needs.

Lantern’s program for ATRT has received Rare Pediatric Disease Designation and Orphan Drug Designation from the FDA, and the company is preparing to submit an investigational new drug (“IND”) amendment.

“We are thrilled with the constructive dialogue and positive feedback from our Type C meeting with the FDA,” Lantern President and CEO Panna Sharma stated in the company’s Sept. 3 news release about the meeting (https://ibn.fm/VgPKC). “This guidance not only reinforces our trial design but also highlights the potential of our AI platform, RADR®, in identifying and optimizing combination regimens like spironolactone for these devastating pediatric CNS cancers.”

Lantern aims to transform cancer treatment through the use of artificial intelligence (“AI”) to identify biomarkers related to the cancers, analyzing genomic data from large populations of individuals to understand disease-related genetic variations. The company then aims to progressively use preclinical modeling to accelerate the development of oncology drugs.

The company’s proprietary computational biology and machine learning platform will be used in the planned Phase 1b/2 trial that will enroll pediatric patients across multiple sites, with primary endpoints focused on progression-free survival, overall response rate, and quality-of-life measures.

Lantern is also using LP-184 in a Phase 1a trial for glioblastoma (“GBM”) and advanced solid tumors such as triple-negative breast cancer (“TNBC”). It also is in a Phase 2 trial using its drug candidate LP-300 for treating non-small cell lung cancer (“NSCLC”) in individuals whose cancer is completely unrelated to smoking tobacco. And the company is using its LP-284 drug candidate in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) and other solid tumors.

The trial of LP-300 in combination with chemotherapy has resulted in a complete response for a 70-year-old non-smoker with advanced non-small cell lung cancer after three prior lines of therapy had failed.

“This quarter we observed complete responses in patients across two of our clinical trials, delivering meaningful patient benefit and providing further validation of both the mechanisms and therapeutic potential of our drug candidates,” Sharma said last month (https://ibn.fm/bHsie). “Simultaneously, our team is transforming our AI platform into functional, accessible modules for the broader oncology community. These parallel advances mark a pivotal inflection point in our clinical and technological evolution.”

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN

Maximizing Gold Leverage While Minimizing Risk

Gold has surged to new record highs – recently surpassing $3,780 per ounce – as investors worldwide turn to the metal’s proven role as a hedge against inflation, currency weakness, and financial-market volatility (ibn.fm/29CUk). With expectations of rate cuts, central bank demand, and softer global growth, analysts see further upside.  In this environment, quality gold mining companies offer powerful leverage, where even modest price increases can generate outsized equity returns.

West Vault Mining (TSX.V: WVM) (OTCQX: WVMDF), a Nevada-focused gold company, has positioned itself to capture this opportunity while carefully controlling downside risk. The company’s strategy is simple: deliver low-risk exposure to high-margin gold ounces in one of the world’s safest, most mining-friendly jurisdictions.

A De-Risked, Permitted Gold Project in Nevada

At the center of West Vault’s strategy is the Hasbrouck Gold Project (ibn.fm/Fz6I1), located near Tonopah, Nevada—the heart of America’s most prolific gold-producing region. Nevada is responsible for over 70% of U.S. gold production, underpinned by world-class geology, modern infrastructure, and a legal framework supportive of mining (ibn.fm/bTeHj).

Unlike many junior miners, West Vault has already advanced Hasbrouck well beyond the conceptual stage:

• All major permits secured for mine development.
• Pre-feasibility study completed, demonstrating strong project economics.
• Strategic location along an established mining corridor, reducing both cost and infrastructure risk.

This disciplined approach translates into lower political, permitting, and execution risk, allowing shareholders to maintain full exposure to rising gold prices without the uncertainties often associated with early-stage exploration.

Proven Leadership With Technical and Financial Strength

West Vault is led by a management and board team whose experience spans mine construction, operations, finance, and capital markets (ibn.fm/VxUSG):

• Sandy McVey, CEO & COO – A Professional Mining Engineer and Project Management Professional with 30+ years in mine construction and operations worldwide.
• Frank R. Hallam, CFO & Director – A Chartered Professional Accountant and co-founder with decades of experience founding and financing successful North American mining companies.
• Peter Palmedo, Chair & Director – Founder of Sun Valley Gold LLC, bringing deep investment expertise and strategic market insight.

This blend of operational credibility and financial acumen provides the company with a strong foundation for executing its development strategy and maintaining investor confidence.

Positioned for a Bullish Gold Cycle

For investors considering gold exposure, West Vault represents a speculative play with upside potential tied to rising gold prices and favorable jurisdictional exposure. If the gold cycle continues and West Vault follows its strategy, the leverage to gold has potential to generate meaningful returns for shareholders.

As the gold market continues its record-setting run, West Vault Mining is well placed to generate value for shareholders – capturing the upside of rising gold prices while mitigating many of the risks that often accompany early-stage mining ventures.

For more information, visit the company’s website at www.WestVaultMining.com.

NOTE TO INVESTORS: The latest news and updates relating to WVMDF are available in the company’s newsroom at ibn.fm/WVMDF

• The White House’s recent proclamation targets copper imports with tariffs to bolster domestic production and national security
• Interior Department proposes adding copper to the U.S. critical minerals list, potentially unlocking federal funding and streamlined permitting for domestic projects
• Trilogy Metals’ Upper Kobuk Mineral Projects in Alaska contain high-grade copper, cobalt, zinc, and other defense-critical metals

The convergence of market demand, national security priorities, and federal policy is reshaping the U.S. copper landscape. Copper, essential for defense systems, infrastructure, and emerging technologies, has become a focal point of strategic concern. The combination of executive action and critical minerals policy highlights the urgent need to secure domestic sources, a development that positions Trilogy Metals (NYSE American: TMQ) (TSX: TMQ) at the center of both economic and national security considerations.

Federal Action Elevates Domestic Copper

In late July 2025, the White House issued a proclamation under Section 232 of the Trade Expansion Act, imposing tariffs of up to 50% on semi-finished and derivative copper products imported into the United States. The administration cited risks to national security from overreliance on foreign supply, particularly as a single country dominates global smelting and refining. Copper’s role across the Department of Defense, including aircraft, vehicles, ships, missiles, and ammunition, was highlighted as critical to maintaining technological and military readiness.

These tariffs aim to stimulate domestic production, incentivize investment in U.S. copper fabrication, and reduce vulnerability to supply chain disruptions. The proclamation also outlines phased domestic sales requirements and export controls for high-quality copper scrap, further bolstering U.S. industrial resilience.

Critical Minerals Listing Expands Support

Complementing tariff measures, the Interior Department proposed adding copper to the draft 2025 critical minerals list. Inclusion would make eligible projects potentially competitive for federal funding, streamlined permitting, and protection from certain import-related fees. Copper’s draft designation underscores its strategic importance amid rising domestic electricity demand, the growth of data centers, and electrification of transportation.

Secretary of the Interior Doug Burgum noted that the draft list provides a roadmap to reduce U.S. dependence on imports while expanding domestic production. Public comment on the proposal is open for 30 days, with the final list expected to further clarify the government’s priorities for supporting strategic mining projects.

Trilogy Metals’ Upper Kobuk Mineral Projects

Trilogy Metals operates through a 50/50 joint venture with South32 at the Upper Kobuk Mineral Projects in Alaska’s Ambler Mining District. The Arctic deposit contains 46.7 million tonnes of probable reserves grading 2.11% copper, 2.9% zinc, and 0.56% lead, complemented by 0.42 g/t gold and 31.8 g/t silver, with a 2023 feasibility study estimating a $1.5 billion pre-tax NPV.

Nearby, the Bornite copper-cobalt project adds an inferred resource of 6.5 billion pounds of copper. Together, Arctic and Bornite offer the potential for a multi-decade mining operation supplying metals essential to defense applications, grid storage, and clean energy technologies – anchored in a high-grade, stable jurisdiction.

Infrastructure as a Strategic Asset

The proposed 211-mile Ambler Access Road, connecting Trilogy’s projects to Alaska’s highway system, has gained strategic significance under new federal policies. Once viewed primarily as economic infrastructure, it now aligns with national security objectives by enabling reliable access to domestic critical minerals. A partnership state-owned corporation Alaska Industrial Development and Export Authority provide technical expertise and community collaboration essential for advancing both permitting and operational readiness.

Market Dynamics Reinforce Policy

Global copper demand continues to rise due to electrification, renewable energy deployment, and the expansion of data centers and AI infrastructure. At the same time, global supply growth is constrained by declining ore grades, extended development timelines, and geopolitical dependencies. Trilogy Metals’ high-grade Arctic and Bornite deposits sit at the nexus of policy and market demand, offering both strategic and economic value.

Strategic Outlook

The intersection of tariffs, critical mineral designation, and strong domestic demand places Trilogy Metals in a unique position. With federal support and infrastructure planning advancing, the company’s Upper Kobuk Mineral Projects could evolve into vital domestic sources of critical minerals, contributing directly to U.S. industrial and defense resilience. As the government continues to emphasize domestic supply security, Trilogy’s Arctic and Bornite deposits may increasingly be seen not only as high-quality mining assets but also as strategic national resources.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ